Related Experiment Video

Updated: Jun 22, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Antiangiogenic effect of a selective 5-HT4 receptor agonist

Takeshi Nishikawa1, Nelson H Tsuno, Yasutaka Shuno

  • 1Department of Surgical Oncology, University of Tokyo, Tokyo, Japan. takn-tky@umin.ac.jp <takn-tky@umin.ac.jp>

The Journal of Surgical Research
|June 12, 2009
PubMed
Abstract

Insights

Mosapride citrate, a serotonin (5-HT4) agonist, demonstrated anti-angiogenic effects by inhibiting endothelial cell proliferation and migration. This suggests its potential as a novel anti-cancer therapeutic agent.

Area of Science:

  • Biomedical research
  • Pharmacology
  • Cancer biology

Background:

  • Serotonin (5-hydroxytryptamine, 5-HT) influences cell growth in various carcinomas.
  • 5-HT has complex effects on blood vessels via multiple 5-HT receptors.
  • Mosapride citrate is a selective 5-HT4 receptor agonist with known prokinetic properties.

Purpose of the Study:

  • To investigate the anti-angiogenic potential of mosapride citrate.
  • To evaluate mosapride citrate's effects on human umbilical vein endothelial cells (HUVECs) in vitro.

Main Methods:

  • Assessed HUVEC proliferation using MTS assay.
  • Performed apoptosis and cell cycle detection assays.
  • Investigated HUVEC adhesion, migration, and tube formation on Matrigel.

Main Results:

  • Mosapride citrate inhibited HUVEC proliferation via cell cycle arrest (G0/G1 phase), not apoptosis.
  • Significantly reduced HUVEC migration and tube-like structure formation.
  • Did not affect HUVEC adhesion to extracellular matrix proteins.

Conclusions:

  • Mosapride citrate exhibits in vitro anti-angiogenic activity.
  • Suggests potential application of mosapride citrate as a novel anti-cancer agent.

More Related Videos

Rat Mesentery Angiogenesis Assay18:30

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...